Glucose-dependent insulinotropic polypeptide/semaglutide - Novo Nordisk
Alternative Names: FDC Sema-OW GIP; Glucose-dependent insulinotropic polypeptide/semaglutide-Novo Nordisk; NN-9389Latest Information Update: 21 Feb 2023
Price :
$50 *
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Hormones; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus